Zobrazeno 1 - 10
of 58
pro vyhledávání: '"P. Kotridis"'
Autor:
P.C. Papadopoulos, B. Kokkas, P. Kotridis, G. Aidonidis, V. Koutsimanis, D. Karnaras, I. Vogiatzis, G. Dadoush, M. Karamouzis, A. Kouyoumtzis, G. Sakantamis, D. Hatseras, C.L. Papadopoulos
Publikováno v:
European Journal of Inflammation, Vol 6 (2008)
The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol on the endogenous anti-hypertensive and anti-inflammatory agent Atrial Natriuretic Peptide (ANP) plasma levels in patients with moderate uncomplicate
Externí odkaz:
https://doaj.org/article/d9b730d748b24cdf867c7db4a926da38
Autor:
P.C. Papadopoulos, P. Kotridis, B. Kokkas, V. Koutsimanis, G. Aidonidis, G. Dadoush, O. Gouli, M. Karamouzis, A. Kouyoumtzis, G. Sakantamis, D. Hatseras, C.L. Papadopoulos
Publikováno v:
European Journal of Inflammation, Vol 5 (2007)
Twenty five patients with moderate essential hypertension were studied for 30 days in order to evaluate the medium term effects of carvedilol on atrial natriuretic peptide (ANP) levels. This drug blocks the β 1 and β 2 adrenenergic receptors as wel
Externí odkaz:
https://doaj.org/article/c929061d3efb48bb93cb441091ac9f9d
Autor:
Vardakis, Iosif, Kotridis, Georgios, Peppas, Spyridon, Skyvalakis, Konstantinos, Vougioukas, Georgios, Bletsas, Aggelos
This work exploits commodity, ultra-low cost, commercial radio frequency identification tags (RFID) as the elements of a reconfigurable surface. Such batteryless tags are powered and controlled by a software-defined (SDR) reader, with properly modifi
Externí odkaz:
http://arxiv.org/abs/2105.14475
Autor:
Vardakis, Iosif, Kotridis, Georgios, Peppas, Spyridon, Skyvalakis, Konstantinos, Vougioukas, Georgios, Bletsas, Aggelos
Publikováno v:
IEEE Transactions on Wireless Communications; 2023, Vol. 22 Issue: 6 p3942-3954, 13p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
B. Kokkas, Gitsios C, Atnanassios G. Paradelis, C.L. Papadopoulos, P. Kotridis, G. Sakadamis, M. Kotoula, John E. Kanonidis
Publikováno v:
International Journal of Angiology. 4:165-168
The aim of this study was to evaluate the effects of the high selective β1-blocker bisoprolol on atrial natriuretic peptide (ANP) plasma levels in patients with a moderate essential hypertension. The study was divided into two parts: a long-term and
Autor:
G. Dadoush, A. Kouyoumtzis, P.C. Papadopoulos, D. Hatseras, B. Kokkas, P. Kotridis, V. Koutsimanis, O. Gouli, M. Karamouzis, C.L. Papadopoulos, G. Sakantamis, G. Aidonidis
Publikováno v:
European Journal of Inflammation, Vol 5 (2007)
Twenty five patients with moderate essential hypertension were studied for 30 days in order to evaluate the medium term effects of carvedilol on atrial natriuretic peptide (ANP) levels. This drug blocks the β1 and β2 adrenenergic receptors as well
Autor:
P. Kotridis, P.C. Papadopoulos, P. Kyriakou, J. Karadoumanis, G. Salpigidis, O. Goulis, A. Dimitriadou, C. Vakalopoulos, M. Karamouzis, T. Ginis, G. Sakantamis, C.L. Papadopoulos, V. Mirtsou-Fidani, B. Kokkas, C. Karantona
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 28:143-146
The aim of this study was to evaluate the medium term effects of the selective alpha1-adrenenergic- blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally for 30 days.
Autor:
P. Kyriakoui, B. Kokkas, P. Kotridis, Theodossiadis, V. Mirtsou-Fidani, G. Dadous, Ioannis Kanonidis, M. Karamouzis, C.L. Papadopoulos, P.C. Papadopoulos, S. Haritos, G. Sakadamis
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 27:45-48
The aim of this study was to evaluate the long term effects of the selective Ca2+-blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 3